Rep Blumenauer On Marijuana Reclassification: ‘Legalization Is Inevitable, Biden-Harris Admin Is Listening’ To The People
In a landmark decision that could reshape the landscape of American drug policy, the U.S. Drug Enforcement Administration (DEA) will reportedly move forward with a proposal to reclassify marijuana as a Schedule III drug, reducing its classification from the highly restrictive Schedule I category, which it shares with substances like heroin and ecstasy. This reclassification recognizes the medical benefits of cannabis and acknowledges its lower potential for abuse compared to other drugs like heroin and LSD that remain in Schedule I.
The proposed shift, which is said to be currently under review by the White House Office of Management and Budget (OMB), marks a significant pivot in drug regulation and could ease research restrictions and change enforcement practices across the nation. Following the review, the DEA plans to invite public comment, an essential step before finalizing the reclassification.
Pro tip: Learn all about the future of the cannabis industry at the Benzinga Cannabis Capital Conference this October in Chicago. Hear directly …